Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.

Abstract

Oncolytic herpes simplex viruses (oHSVs) are engineered to target and replicate specifically in tumor cells, minimizing damage to normal tissues. This live virus biotherapy entails direct tumor cell killing followed by stimulation of anti-tumor immunity, leading to abscopal effects in untreated lesions. Currently, there are two clinically approved oHSV biotherapeutics: Imlygic, marketed by Amgen for treatment of advanced melanoma in USA and Europe, and Delytact, conditionally approved for recurrent brain tumors in Japan. Lessons learnt from initial testing in patients have led to the development of second-generation viruses designed to improve tumor cytotoxicity and/or anti-tumor immune responses. Preclinical research has also uncovered numerous virus-drug interactions predicted to be synergistic. This has resulted in numerous clinical trials that are currently evaluating these second-generation viruses as single agents or in combination with other anti-neoplastic therapeutics. As of this review, there are more than one hundred clinical trials evaluating their safety and efficacy. Here, we lay out a summary of oHSVs and the rationale behind various virus-drug combinations in clinical trials for patients with different malignancies. We provide a comprehensive review that details the underlying mechanisms of oHSV design and virus-drug interactions that form the basis of their clinical investigation.